Glucagon analogues
AssigneeNovo Nordisk A/S
InventorsJesper F. Lau, Thomas Kruse, Henning Thoegersen, Ulrich Sensfuss, Peter Kresten Nielsen
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel glucagon peptides, to the use of said glucagon peptides in therapy, to methods of treatment comprising administration of said glucagon peptides to patients in need thereof, and to the use of said glucagon peptides in the manufacture of medicaments. The glucagon peptides of the present invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity.
Claims41
A glucagon peptide comprising:
- SEQ ID NO:
- 1, wherein X24 is Lys and wherein at least one of the following substitutions are present:
- X3 is His, X15 is Glu or X16 is Ala, Ile, Phe, Arg, Thr, Val, Leu, Glu, Trp or Tyr and up to six additional amino acid substitutions in said glucagon peptide;
- and
- a substituent comprising three or more negatively charged moieties, wherein one of the said negatively charged moieties is distal of a lipophilic moiety and where the substituent is attached at the side chain nitrogen of Lys in position 24,
- or a pharmaceutically acceptable salt, ester, amide, acid or prodrug thereof.
A pharmaceutical composition comprising a glucagon peptide comprising:
- SEQ ID NO:
- 1, wherein X24 is Lys and wherein at least one of the following substitutions are present:
- X3 is His, X15 is Glu or X16 is Ala, Ile, Phe, Arg, Thr, Val, Leu, Glu, Trp or Tyr and up to six additional amino acid substitutions in said glucagon peptide;
- and
- a substituent comprising three or more negatively charged moieties, wherein one of the said negatively charged moieties is distal of a lipophilic moiety and where the substituent is attached at the side chain nitrogen of Lys in position 24,
- or a pharmaceutically acceptable salt, ester, amide, acid or prodrug thereof.
A method for reducing bodyweight comprising administering to a patient in need thereof an effective amount of a glucagon peptide comprising
- SEQ ID NO:
- 1, wherein X24 is Lys and wherein at least one of the following substitutions are present:
- X3 is His, X15 is Glu or X16 is Ala, Ile, Phe, Arg, Thr, Val, Leu, Glu, Trp or Tyr and up to six additional amino acid substitutions in said glucagon peptide;
- and
- a substituent comprising three or more negatively charged moieties, wherein one of the said negatively charged moieties is distal of a lipophilic moiety and where the substituent is attached at the side chain nitrogen of Lys in position 24,
- or a pharmaceutically acceptable salt, ester, amide, acid or prodrug thereof.
Dependencies are inferred from the claim text.